Group 1 - The company has signed a technology transfer contract with Shandong University of Traditional Chinese Medicine Affiliated Hospital for the development of a new traditional Chinese medicine product [2][3] - The total technology transfer fee is set at 15 million yuan, which will be paid in installments as per the contract [6] - The contract includes provisions for intellectual property rights, ensuring that the technology and any resulting innovations will belong to the company, while the hospital retains certain academic rights [7][8] Group 2 - The technology being transferred involves the "Er Zhi Tiao Jing Optimization Formula," aimed at developing a new drug for treating conditions related to kidney deficiency [2][3] - The company is responsible for conducting all necessary research and regulatory submissions to achieve national drug registration for the new product [5] - The contract stipulates confidentiality obligations that extend for 20 years post-termination, ensuring that sensitive information remains protected [11][12] Group 3 - The contract outlines specific conditions under which either party can terminate the agreement, including failure to meet research milestones or submission deadlines [13][14] - Dispute resolution will be handled through negotiation, and if unresolved, will be taken to the competent court [17] - The contract is valid for 20 years and requires mutual consent for any amendments [20]

Group 1 - The company held its 29th meeting of the fifth board of directors on August 15, 2025, where all 9 attending directors approved the agenda items [1][4] - The company’s subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., plans to sign a technology transfer contract with Shandong University of Traditional Chinese Medicine Hospital for the transfer of a traditional Chinese medicine formula for a total price of 15 million RMB [11][14] - The board approved the change of address for another subsidiary, Shandong Buchang Golden Key Pharmaceutical Technology Co., Ltd., due to operational management needs [5][26] Group 2 - The technology transfer agreement aims to enhance the company's product development pipeline and strengthen market competitiveness [21] - The financial data of Shandong Danhong as of December 31, 2024, shows total assets of 2.768 billion RMB, total liabilities of 1.487 billion RMB, and net assets of 1.281 billion RMB [18] - The financial data of Shandong University of Traditional Chinese Medicine Hospital as of June 30, 2025, indicates total assets of 5.570 billion RMB, total liabilities of 2.268 billion RMB, and net assets of 3.303 billion RMB [20]